Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice
Longbrake EE, Cross AH, Salter A. Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice. Multiple Sclerosis Journal - Experimental Translational And Clinical 2016, 2: 2055217316677868. PMID: 28280599, PMCID: PMC5340186, DOI: 10.1177/2055217316677868.Peer-Reviewed Original ResearchDisease-modifying therapiesMultiple sclerosis activityInjectable disease-modifying therapiesOral disease-modifying therapiesMultiple sclerosisInjectable therapiesBaseline differencesClinical practiceRetrospective cohort studyProportional hazards modelDrug discontinuationCohort studyDiscontinuation ratesTreatment groupsHazards modelSclerosisPatientsTherapyRelative efficacyTolerabilityFurther studiesHigher proportionEfficacyExpert opinionTreatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply